APA (7th ed.) Citation

Chen, F., Feng, X., Xiao, L. L., Tang, H. J., Qin, S. X., Peng, J. P., & Bai, J. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Chen, Feng, Xue Feng, Lin Lin Xiao, Hai Juan Tang, Shu Xia Qin, Jie Ping Peng, and Jing Bai. Cost-effectiveness Analysis of First-line Tislelizumab Plus Chemotherapy for Extensive-stage Small Cell Lung Cancer from the Perspective of the Healthcare System in China. Frontiers Media S.A.

MLA (9th ed.) Citation

Chen, Feng, et al. Cost-effectiveness Analysis of First-line Tislelizumab Plus Chemotherapy for Extensive-stage Small Cell Lung Cancer from the Perspective of the Healthcare System in China. Frontiers Media S.A.